Overview
No overview information available.
Indication
No indication information available.
Associated Conditions
No associated conditions information available.
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
---|---|---|---|---|---|
2021/12/15 | Phase 3 | Completed | |||
2020/11/18 | Phase 3 | Completed | |||
2019/12/10 | Phase 3 | Active, not recruiting | |||
2019/07/24 | Phase 3 | Completed | |||
2019/07/11 | Phase 3 | Completed | |||
2019/05/15 | Phase 3 | Completed | |||
2019/02/20 | Phase 1 | Completed |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
---|---|---|---|---|---|
No FDA approvals found for this drug. |
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
---|---|---|---|
No EMA approvals found for this drug. |
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
APEXXNAR SUSPENSION FOR INJECTION IN SINGLE-DOSE PRE-FILLED SYRINGE 0.5ML | SIN16648P | INJECTION, SUSPENSION | Approx. 51 μg/0.5ml | 11/30/2022 | |
Prevenar 13 Suspension For Injection | SIN13824P | INJECTION, SUSPENSION | 32mcg | 7/2/2010 |
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
---|---|---|---|---|---|
No NMPA approvals found for this drug. |
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
---|---|---|---|---|---|
No PPB approvals found for this drug. |
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
---|---|---|---|---|---|
MENVEO Meningococcal (Groups A,C,W-135 and Y) Oligosaccharide CRM197 solution for injection vial | 393321 | Medicine | A | 9/26/2023 | |
MENVEO meningococcal (Groups A, C, W-135 and Y) oligosaccharide CRM197 conjugate vaccine | 192696 | Medicine | A | 5/23/2012 |
Health Canada Drug Approvals
Approved Product | Company | DIN | Dosage Form | Strength | Market Date |
---|---|---|---|---|---|
MENINGITEC | nuron biotech b.v. | 02248649 | Suspension - Intramuscular | 15 MCG / 0.5 ML | 2/23/2004 |
PREVNAR 13 | 02335204 | Suspension - Intramuscular | 34 MCG / 0.5 ML | 3/1/2010 | |
PREVNAR | 02244081 | Suspension - Intramuscular | 20 MCG / 0.5 ML | 6/20/2001 | |
PREVNAR 20 | 02527049 | Suspension - Intramuscular | 51 MCG / 0.5 ML | 7/8/2022 | |
MENVEO | 02347393 | Solution
,
Powder For Solution - Intramuscular | 47 MCG / 0.5 ML | 7/29/2010 | |
MENJUGATE | 02243820 | Powder For Suspension - Intramuscular | 25 MCG / 0.5 ML | 9/5/2001 | |
HIBTITER SOL INJ | praxis biologics inc. | 01943146 | Liquid - Intramuscular | 25 MCG / 0.5 ML | 12/31/1992 |
VAXNEUVANCE | Merck Canada Inc | 02522403 | Suspension - Intramuscular | 30 MCG / 0.5 ML | 9/2/2022 |
MENJUGATE LIQUID | 02440709 | Suspension - Intramuscular | 25 MCG / 0.5 ML | 10/7/2015 | |
CAPVAXIVE | Merck Canada Inc | 02549891 | Solution - Intramuscular | 65 MCG / 0.5 ML | 8/29/2024 |
CIMA AEMPS Drug Approvals
Approved Product | Company | Registration Number | Pharmaceutical Form | Prescription Type | Status |
---|---|---|---|---|---|
No CIMA AEMPS (Spain) approvals found for this drug. |
Philippines FDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No Philippines FDA approvals found for this drug. |
Saudi SFDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No Saudi SFDA approvals found for this drug. |
Malaysia NPRA Drug Approvals
Approved Product | Company | Registration Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No Malaysia NPRA approvals found for this drug. |
UK EMC Drug Information
Medicine Name | MA Holder | MA Number | Pharmaceutical Form | Active Ingredient | Authorization Date |
---|---|---|---|---|---|
No UK EMC drug information found for this drug. |
Help Us Improve
Your feedback helps us provide better drug information and insights.